Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
ADAR1 Capital Management, the largest shareholder of Keros Therapeutics (NASDAQ: KROS) with a 13.3% stake, has released an investor presentation detailing its reasons for opposing the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the company's Board of Directors. The decision will be voted on at Keros' Annual Meeting of Stockholders scheduled for June 4, 2025.
Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in the Bank of America 2025 Global Healthcare Conference. The company's CEO, Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on May 13, 2025, at 8:00 p.m. Eastern time. The presentation will be accessible via live webcast, with a replay available on the company's investor relations website for 90 days after the event.
Keros Therapeutics (NASDAQ: KROS) has responded to ADAR1 Capital Management's recent communications regarding the upcoming 2025 Annual Meeting. The company's Board announced it is conducting a strategic review process through an independent committee to evaluate options including a potential sale, continued pipeline investment, or return of capital to shareholders. The review follows a significant $200 million upfront payment from a licensing deal with Takeda, which could yield up to $1.1 billion in additional milestones plus royalties.
ADAR1 has opposed the re-election of two independent directors unless their CIO is added to the Board, pushing for immediate capital return to shareholders. Keros's Board, comprising nine directors (eight independent), recommends shareholders vote "FOR" its three director nominees at the June 4, 2025 Annual Meeting. The company highlights its strong cash position, funding operations into 2029.
ADAR1 Capital Management, Keros Therapeutics' (NASDAQ: KROS) largest stockholder with a 13.3% stake, has released an open letter expressing concerns about the company's performance and direction. The activist investor announced plans to withhold votes for directors Dr. Mary Ann Gray and Dr. Alpna Seth at the June 4, 2025 stockholder meeting.
ADAR1 criticizes Keros for concerning clinical results in two drug candidates (KER-012 and KER-065) and calls for major restructuring, including a 70% headcount reduction and return of excess capital to shareholders. The company holds over $720 million in cash as of March 31, 2025. ADAR1 believes their proposed changes could deliver $24-35 per share in value, focusing on KER-050's partnership with Takeda, which they estimate could achieve $2 billion in peak sales.